HRP20211926T1 - Konstrukti proteina uspa2 i njihova upotreba - Google Patents
Konstrukti proteina uspa2 i njihova upotreba Download PDFInfo
- Publication number
- HRP20211926T1 HRP20211926T1 HRP20211926TT HRP20211926T HRP20211926T1 HR P20211926 T1 HRP20211926 T1 HR P20211926T1 HR P20211926T T HRP20211926T T HR P20211926TT HR P20211926 T HRP20211926 T HR P20211926T HR P20211926 T1 HRP20211926 T1 HR P20211926T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- seq
- pila
- vaccine
- immunogenic preparation
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 11
- 108090000623 proteins and genes Proteins 0.000 title claims 11
- 230000002163 immunogen Effects 0.000 claims 9
- 229960005486 vaccine Drugs 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 4
- 101710188053 Protein D Proteins 0.000 claims 4
- 101710132893 Resolvase Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 241000588655 Moraxella catarrhalis Species 0.000 claims 2
- 241001377010 Pila Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 102000007547 Laminin Human genes 0.000 claims 1
- 108010085895 Laminin Proteins 0.000 claims 1
- 241001092142 Molina Species 0.000 claims 1
- 241001454523 Quillaja saponaria Species 0.000 claims 1
- 101710088839 Replication initiation protein Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000009798 acute exacerbation Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (15)
1. Protein formule I:
A—(R1)m—(B)n (formula I)
naznačen time što:
A je imunogeni fragment UspA2 iz bakterije Moraxella catarrhalis koji je najmanje 90% istovjetan SEQ ID NO: 43;
R1 je aminokiselina;
m je 0;
B je histidin; i
n je 1, 2, 3, 4, 5 ili 6.
2. Protein u skladu s patentnim zahtjevom 1, naznačen time što n je 2.
3. Protein u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što dodatno sadrži metionin na amino kraju.
4. Protein u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je A SEQ ID NO: 43.
5. Protein u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je A imunogeni fragment UspA2 koji sadrži domenu koja se veže na laminin, domenu koja se veže na fibronektin i domenu koja se veže na C3.
6. Imunogeni pripravak, naznačen time što sadrži protein formule (I) u skladu s bilo kojim od patentnim zahtjevima 1-5.
7. Imunogeni pripravak u skladu s patentnim zahtjevom 6, naznačen time što dodatno sadrži najmanje jedan antigen iz bakterije Haemophilus influenzae, gdje je najmanje jedan antigen protein D.
8. Imunogeni pripravak u skladu s patentnim zahtjevom 7, naznačen time što dodatno sadrži protein E i PilA, gdje su PE i PilA prisutni u obliku fuzijskog proteina.
9. Cjepivo, naznačeno time što sadrži protein u skladu s bilo kojim od patentnih zahtjeva 1-5 ili imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 6-8.
10. Cjepivo u skladu s patentnim zahtjevom 9, naznačen time što imunogeni pripravak sadrži protein sa SEQ ID NO: 69, protein D i fuzijski protein PE-PilA, gdje fuzijski protein PE-PilA može biti LVL-735, te gdje navedeni pripravak sadrži pomoćno sredstvo kojeg se bira između arginina, pluronske kiseline i/ili polisorbata.
11. Cjepivo u skladu s bilo kojim od patentnih zahtjeva 9-10, naznačeno time što sadrži (i) 10 µg proteina D, 10 µg fuzijskog proteina PE-PilA (LVL735), 10 µg konstrukta UspA2 sa SEQ ID NO: 69 (MC-009) i adjuvans AS01E, ili (ii) 10 µg proteina D, 10 µg fuzijskog proteina PE-PiIA LVL735, 3,3 µg konstrukta UspA2 sa SEQ ID NO: 69 (MC-009) i adjuvans AS01E.
12. Cjepivo u skladu s patentnim zahtjevom 11, naznačen time što adjuvans AS01E sadrži 3-O-deacil-4’ monofosforilirani lipid A (MPL), frakciju 21 iz biljke Quillaja saponaria Molina (QS21) i liposome (25 µg MPL i 25 µg QS21).
13. Cjepivo u skladu s patentnim zahtjevima 9-12, naznačen time što je prilagođeno za intramuskularnu primjenu.
14. Protein u skladu s patentnim zahtjevima 1-5, ili imunogeni pripravak u skladu s patentnim zahtjevima 6-8, ili cjepivo u skladu s patentnim zahtjevima 9-13, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju akutnih pogoršanja kronične opstruktivne plućne bolesti (AECOPD).
15. Protein u skladu s patentnim zahtjevima 1-5, ili imunogeni pripravak u skladu s patentnim zahtjevima 6-8, ili cjepivo u skladu s patentnim zahtjevima 9-13, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju infekcije ili bolesti koju uzrokuje bakterija M. catarrhalis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943909P | 2014-02-24 | 2014-02-24 | |
| US201461946937P | 2014-03-03 | 2014-03-03 | |
| US201461946932P | 2014-03-03 | 2014-03-03 | |
| EP18211544.4A EP3498292B1 (en) | 2014-02-24 | 2015-02-20 | Uspa2 protein constructs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211926T1 true HRP20211926T1 (hr) | 2022-03-18 |
Family
ID=52629643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211926TT HRP20211926T1 (hr) | 2014-02-24 | 2015-02-20 | Konstrukti proteina uspa2 i njihova upotreba |
| HRP20190412TT HRP20190412T1 (hr) | 2014-02-24 | 2019-03-04 | Konstrukti proteina uspa2 i njihova upotreba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190412TT HRP20190412T1 (hr) | 2014-02-24 | 2019-03-04 | Konstrukti proteina uspa2 i njihova upotreba |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10040832B2 (hr) |
| EP (2) | EP3110438B1 (hr) |
| JP (1) | JP6585085B2 (hr) |
| KR (1) | KR102515835B1 (hr) |
| CN (2) | CN111499701A (hr) |
| AU (1) | AU2015220369B2 (hr) |
| BE (1) | BE1022345A9 (hr) |
| BR (1) | BR112016019525B1 (hr) |
| CA (1) | CA2939862C (hr) |
| CY (2) | CY1121535T1 (hr) |
| DK (2) | DK3110438T3 (hr) |
| EA (1) | EA034352B1 (hr) |
| ES (2) | ES2715674T3 (hr) |
| HR (2) | HRP20211926T1 (hr) |
| HU (2) | HUE057505T2 (hr) |
| IL (1) | IL246994B (hr) |
| LT (2) | LT3498292T (hr) |
| ME (1) | ME03335B (hr) |
| MX (1) | MX2016010954A (hr) |
| PL (2) | PL3110438T3 (hr) |
| PT (2) | PT3110438T (hr) |
| RS (2) | RS58451B1 (hr) |
| SG (1) | SG11201606272PA (hr) |
| SI (2) | SI3110438T1 (hr) |
| TW (1) | TW201620927A (hr) |
| UY (1) | UY36006A (hr) |
| WO (1) | WO2015125118A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| EP3600391A1 (en) | 2017-03-31 | 2020-02-05 | GlaxoSmithKline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| GB2600652B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel compositions |
| WO2019034575A1 (en) | 2017-08-14 | 2019-02-21 | Glaxosmithkline Biologicals Sa | METHODS OF AMPLIFYING IMMUNE RESPONSES |
| JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| GB201803692D0 (en) * | 2018-03-08 | 2018-04-25 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN112601545A (zh) | 2018-08-07 | 2021-04-02 | 葛兰素史密丝克莱恩生物有限公司 | 工艺和疫苗 |
| US20210220462A1 (en) * | 2018-08-23 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Immunogenic proteins and compositions |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| CN114080393A (zh) | 2019-06-05 | 2022-02-22 | 葛兰素史克生物有限公司 | 皂苷纯化 |
| BR112021026565A2 (pt) | 2019-08-05 | 2022-05-03 | Glaxosmithkline Biologicals Sa | Composição imunogênica |
| BR112021026775A2 (pt) | 2019-08-05 | 2022-05-10 | Glaxosmithkline Biologicals Sa | Processo para preparar uma composição que compreende um polipeptídeo de proteína d |
| US20230266317A1 (en) | 2019-09-11 | 2023-08-24 | Glaxosmithkline Biologicals Sa | Antigen binding protein and assays |
| JP2024510717A (ja) | 2021-02-22 | 2024-03-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物、使用及び方法 |
| WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | アジュバント含有ワクチン組成物 |
| EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| BR9714160A (pt) * | 1996-12-20 | 2000-05-02 | Univ Texas | Antìgenos uspa1 e uspa2 de moraxella catarrhalis |
| WO2002026757A2 (en) | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| AU2002258734A1 (en) | 2001-04-13 | 2002-10-28 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| MXPA04000653A (es) * | 2001-07-27 | 2004-11-22 | Chiron Srl | Adhesinas de meningococcus nada, app y orf 40. |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| CN101243104B (zh) * | 2005-08-10 | 2012-07-18 | 阿恩·福斯格伦股份公司 | 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用 |
| EP2548884B1 (en) * | 2005-08-10 | 2017-08-02 | Arne Forsgren AB | Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| JP5275814B2 (ja) * | 2006-01-17 | 2013-08-28 | フオルスレン，アルネ | 新規表面露出ヘモフィルス・インフルエンザ（ＨＡＥＭＯＰＨＩＬＵＳＩＮＦＬＵＥＮＺＡＥ）タンパク質（タンパク質Ｅ；ｐＥ） |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| EP2707024A4 (en) * | 2011-05-11 | 2015-03-04 | Riesbeck Healthcare Sweden Ab | PROTEIN F - A NEW HAEMOPHILUS INFLUENZAE ADHESINE WITH LAMININ AND VITRONECTIN BINDING CHARACTERISTICS |
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
-
2015
- 2015-02-17 TW TW104105745A patent/TW201620927A/zh unknown
- 2015-02-20 KR KR1020167022954A patent/KR102515835B1/ko active IP Right Grant
- 2015-02-20 PT PT15708341T patent/PT3110438T/pt unknown
- 2015-02-20 BE BE20155094A patent/BE1022345A9/fr not_active IP Right Cessation
- 2015-02-20 AU AU2015220369A patent/AU2015220369B2/en active Active
- 2015-02-20 DK DK15708341.1T patent/DK3110438T3/en active
- 2015-02-20 HU HUE18211544A patent/HUE057505T2/hu unknown
- 2015-02-20 PL PL15708341T patent/PL3110438T3/pl unknown
- 2015-02-20 ES ES15708341T patent/ES2715674T3/es active Active
- 2015-02-20 CN CN202010194047.1A patent/CN111499701A/zh active Pending
- 2015-02-20 RS RS20190297A patent/RS58451B1/sr unknown
- 2015-02-20 SI SI201530667T patent/SI3110438T1/sl unknown
- 2015-02-20 HU HUE15708341A patent/HUE042054T2/hu unknown
- 2015-02-20 JP JP2016570199A patent/JP6585085B2/ja active Active
- 2015-02-20 RS RS20211446A patent/RS62592B1/sr unknown
- 2015-02-20 CN CN201580010155.6A patent/CN106061995A/zh active Pending
- 2015-02-20 HR HRP20211926TT patent/HRP20211926T1/hr unknown
- 2015-02-20 MX MX2016010954A patent/MX2016010954A/es active IP Right Grant
- 2015-02-20 DK DK18211544.4T patent/DK3498292T3/da active
- 2015-02-20 SI SI201531759T patent/SI3498292T1/sl unknown
- 2015-02-20 US US15/119,220 patent/US10040832B2/en active Active
- 2015-02-20 EP EP15708341.1A patent/EP3110438B1/en active Active
- 2015-02-20 PT PT182115444T patent/PT3498292T/pt unknown
- 2015-02-20 ES ES18211544T patent/ES2899300T3/es active Active
- 2015-02-20 EP EP18211544.4A patent/EP3498292B1/en active Active
- 2015-02-20 LT LTEP18211544.4T patent/LT3498292T/lt unknown
- 2015-02-20 EA EA201691611A patent/EA034352B1/ru not_active IP Right Cessation
- 2015-02-20 WO PCT/IB2015/051308 patent/WO2015125118A1/en active Application Filing
- 2015-02-20 SG SG11201606272PA patent/SG11201606272PA/en unknown
- 2015-02-20 PL PL18211544T patent/PL3498292T3/pl unknown
- 2015-02-20 ME MEP-2019-54A patent/ME03335B/me unknown
- 2015-02-20 LT LTEP15708341.1T patent/LT3110438T/lt unknown
- 2015-02-20 BR BR112016019525-6A patent/BR112016019525B1/pt active IP Right Grant
- 2015-02-20 UY UY0001036006A patent/UY36006A/es not_active Application Discontinuation
- 2015-02-20 CA CA2939862A patent/CA2939862C/en active Active
-
2016
- 2016-07-28 IL IL246994A patent/IL246994B/en active IP Right Grant
-
2018
- 2018-06-29 US US16/023,164 patent/US10745449B2/en active Active
-
2019
- 2019-03-04 HR HRP20190412TT patent/HRP20190412T1/hr unknown
- 2019-03-14 CY CY20191100307T patent/CY1121535T1/el unknown
-
2020
- 2020-06-29 US US16/914,750 patent/US10947280B2/en active Active
-
2021
- 2021-11-30 CY CY20211101038T patent/CY1124979T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211926T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| HRP20200466T1 (hr) | Fuzijski proteini i kombinacijska cjepiva | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| JP2017507181A5 (hr) | ||
| JP2017081939A5 (hr) | ||
| HRP20170251T1 (hr) | Peptidi, konjugati i postupak za povećanje imunogenosti cjepiva | |
| RU2015146614A (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| HRP20220717T1 (hr) | Modificirani pripravci mrna | |
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| HRP20240042T1 (hr) | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci | |
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| JP2016502515A5 (hr) | ||
| JP2016514713A5 (hr) | ||
| JP2016522259A5 (hr) | ||
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| JP2015529677A5 (hr) | ||
| BR112016012306A2 (pt) | peptídeos ricos em prolina para proteção contra s. pneumoniae | |
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
| JP2019534242A5 (hr) | ||
| JP2017521490A5 (hr) | ||
| MX2020001820A (es) | Metodos para reforzar las respuestas inmunitarias. | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| RU2015113230A (ru) | Домен CNAB SDRE STAPHYLOCOCCUS AUREUS и его применение для вакцинации |